Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease

Neurobiology of Disease

Volumn 24, Issue 3, 2006, Pages 516-524

  Garcia Alloza, Monica ^a   Robbins, Elissa M ^a   Zhang Nunes, Sandy X ^a   Purcell, Susan M ^a   Betensky, Rebecca A ^b   Raju, Susan ^a   Prada, Claudia ^a   Greenberg, Steven M ^a   Bacskai, Brian J ^a   Frosch, Matthew P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer disease; Amyloid ; APPswe PS1dE9; Cerebral amyloid angiopathy; Transgenic mouse

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; EX VIVO STUDY; EXON; HISTOCHEMISTRY; IN VIVO STUDY; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SENILE PLAQUE; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; SENILE PLAQUES; TISSUE DISTRIBUTION;

EID: 33750819632     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.08.017     Document Type: Article

References (45)

1. Andra K., Abramowski D., Duke M., Probst A., Wiederhold K.H., Burki K., Goedert M., Sommer B., and Staufenbiel M. Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol. Aging 17 (1996) 183-190
2. Bloom F.E., Reilly J.F., Redwine J.M., Wu C.C., Young W.G., and Morrison J.H. Mouse models of human neurodegenerative disorders: requirements for medication development. Arch. Neurol. 62 (2005) 185-187
3. Borchelt D.R., Lee M.K., Gonzales V., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Price D.L., and Sisodia S.S. Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice. Neurobiol. Aging. 23 (2002) 171-177
4. Christie R., Yamada M., Moskowitz M., and Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 158 (2001) 1065-1071
5. Christie R.H., Bacskai B.J., Zipfel W.R., Williams R.M., Kajdasz S.T., Webb W.W., and Hyman B.T. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J. Neurosci. 21 (2001) 858-864
6. Domnitz S.B., Robbins E.M., Hoang A.W., Garcia-Alloza M., Hyman B.T., Rebeck G.W., Greenberg S.M., Bacskai B.J., and Frosch M.P. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 64 (2005) 588-594
7. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
8. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., and Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262 (1989) 2551-2556
9. German D.C., and Eisch A.J. Mouse models of Alzheimer's disease: insight into treatment. Rev. Neurosci. 15 (2004) 353-369
10. Hardy J., and Cullen K. Amyloid at the blood vessel wall. Nat. Med. 12 (2006) 756-757
11. Herreman A., Hartmann D., Annaert W., Saftig P., Craessaerts K., Serneels L., Umans L., Schrijvers V., Checler F., Vanderstichele H., Baekelandt V., Dressel R., Cupers P., Huylebroeck D., Zwijsen A., Van Leuven F., and De Strooper B. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11872-11877
12. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., and Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4 (1998) 97-100
13. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
14. Hyman B.T., Marzloff K., and Arriagada P.V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol. 52 (1993) 594-600
15. Hyman B.T., West H.L., Rebeck G.W., Buldyrev S.V., Mantegna R.N., Ukleja M., Havlin S., and Stanley H.E. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3586-3590
16. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., and Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13 (2004) 159-170
17. Jankowsky J.L., Slunt H.H., Gonzales V., Jenkins N.A., Copeland N.G., and Borchelt D.R. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol. Aging 25 (2004) 885-892
18. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., and Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17 (2001) 157-165
19. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 109 (2002) 813-836
20. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21 (2001) 372-381
21. Lee J.M., Yin K., Hsin I., Chen S., Fryer J.D., Holtzman D.M., Hsu C.Y., and Xu J. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J. Neurol. Sci. 229-230 (2005) 249-254
22. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., and McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
23. Liu L., Herukka S.K., Minkeviciene R., van Groen T., and Tanila H. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol. Dis. 17 (2004) 516-523
24. McLellan M.E., Kajdasz S.T., Hyman B.T., and Bacskai B.J. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 23 (2003) 2212-2217
25. Mehta N.D., Refolo L.M., Eckman C., Sanders S., Yager D., Perez-Tur J., Younkin S., Duff K., Hardy J., and Hutton M. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. 43 (1998) 256-258
26. Nicoll J.A., Yamada M., Frackowiak J., Mazur-Kolecka B., and Weller R.O. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Aging. 25 (2004) 589-597 (discussion 603-584)
27. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L., Bowler J.V., Ballard C., DeCarli C., Gorelick P.B., Rockwood K., Burns A., Gauthier S., and DeKosky S.T. Vascular cognitive impairment. Lancet Neurol. 2 (2003) 89-98
28. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
29. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., and Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10914-10919
30. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., and DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25 (2005) 629-636
31. Richards J.G., Higgins G.A., Ouagazzal A.M., Ozmen L., Kew J.N., Bohrmann B., Malherbe P., Brockhaus M., Loetscher H., Czech C., Huber G., Bluethmann H., Jacobsen H., and Kemp J.A. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 23 (2003) 8989-9003
32. Robbins E.M., Betensky R.A., Domnitz S.B., Purcell S.M., Garcia-Alloza M., Greenberg C., Rebeck G.W., Hyman B.T., Greenberg S.M., Frosch M.P., and Bacskai B.J. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J. Neurosci. 26 (2006) 365-371
33. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., and Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18 (2005) 602-617
34. Savonenko A.V., Xu G.M., Price D.L., Borchelt D.R., and Markowska A.L. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol. Dis. 12 (2003) 194-211
35. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
36. Selkoe D.J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8 (1998) 447-453
37. Selkoe D.J. The ups and downs of Abeta. Nat. Med. 12 (2006) 758-759
38. Siman R., Reaume A.G., Savage M.J., Trusko S., Lin Y.G., Scott R.W., and Flood D.G. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J. Neurosci. 20 (2000) 8717-8726
39. Spires T.L., and Hyman B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2 (2005) 423-437
40. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13287-13292
41. Weller R.O., Cohen N.R., and Nicoll J.A. Cerebrovascular disease and the pathophysiology of Alzheimer's disease. Implications for therapy. Panminerva Med. 46 (2004) 239-251
42. Weller R.O., Massey A., Kuo Y.M., and Roher A.E. Cerebral amyloid angiopathy: accumulation of A beta in interstitial fluid drainage pathways in Alzheimer's disease. Ann. N. Y. Acad. Sci. 903 (2000) 110-117
43. Wengenack T.M., Whelan S., Curran G.L., Duff K.E., and Poduslo J.F. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101 (2000) 939-944
44. Winkler D.T., Bondolfi L., Herzig M.C., Jann L., Calhoun M.E., Wiederhold K.H., Tolnay M., Staufenbiel M., and Jucker M. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 21 (2001) 1619-1627
45. Zhang-Nunes S.X., Maat-Schieman M.L.C., Van Duinen S.G., Roos R.A.C., Frosch M.P., and Greenberg S.M. The cerebral β-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 16 (2006) 30-39